XMT-2056

DB18230InvestigationalProtein Based Therapies

XMT-2056 is a HER2-targeted antibody-drug conjugate (ADC) consisting of a HER2-targeted antibody conjugated with a stimulator of interferon genes (STING) agonist payload.

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-2 and Stimulator of interferon genes protein
Curator reviewed
Code names: XMT-2056

Resolves to

Targets

P04626ERBB2Q86WV6STING1

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with XMT-2056, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account